MultiVu Video Feed: The New England Journal of Medicine Publishes Nexavar(R) Study...

MultiVu Video Feed: The New England Journal of Medicine Publishes Nexavar(R)
Study Demonstrating Significant Improvement In Overall Survival In Patients
With Liver Cancer

- Nexavar is First Approved Systemic Therapy to Treat the Disease -
Liver cancer is the sixth most common cancer in the world and the third
leading cause of cancer-related deaths globally.
A recent study published in The New England Journal of Medicine showed
results of a Phase 3 trial demonstrating that Nexavar(R) (sorafenib) tablets
decreased the absolute risk of death by 31 percent in patients with
unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients
who received placebo. This represents a 44 percent improvement in median
overall survival for patients treated with Nexavar. Based on the strength of
these data, Nexavar was approved for HCC by the European Agency for the
Evaluation of Medicinal Products (EMEA) and by the U.S. Food and Drug
Administration (FDA) in October and November 2007, respectively.
Hepatocellular carcinoma is the most common form of liver cancer and is
responsible for about 90 percent of the primary malignant liver tumors in
adults. In 2002, approximately 600,000 people died of liver cancer including
approximately 370,000 in China. South Korea and Japan, 57,000 in the European
Union, and 13,000 in the United States.
SATELLITE FEEDS:
Wednesday, July 23rd, 2008 Thursday, July 24th, 2008
6:30 PM - 6:45 PM ET 1:00 PM - 1:15 PM ET
Galaxy 25 Galaxy 11
C-Band C-Band
Transponder 1 Transponder 10
Downlink Freq. 3720 Vertical Downlink Freq. 3900 Vertical

NEWS: Study in the NEJM Shows Nexavar(R) Helped Decrease Risk of Death in
Liver Cancer Patients
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at:
http://www.prnewswire.com/broadcast/31156/press.html

SOUNDBITES:
* Josep Llovet, M.D., Co-principal investigator & Professor of Research
Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit
Hospital Clinic Barcelona & Director of Research, HCC Program,
Associate Professor, Medicine Mount Sinai School of Medicine
* Ray, Liver Cancer patient
* David Reade, Liver Cancer Patient

B-ROLL INCLUDES:
* NEJM Page, Mechanism of Action, Nexavar Pill Bottles, Manufacturing
Footage, Mount Sinai Exteriors, Lab Footage, Doctor Footage, Patient
Lifestyle footage

VIDEO PROVIDED BY: Bayer HealthCare Pharmaceuticals, Inc. and Onyx
Pharmaceuticals, Inc.
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,
1-800-653-5313 EXT. 3
SOURCE Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.

FOR TECHNICAL INFORMATION OR HARD COPY, PLEASE CALL: MultiVu Media Relations,
1-800-653-5313 EXT. 3